# PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

> **NCT01734512** · PHASE2 · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 65 (actual)

## Conditions studied

- Pediatric Recurrent Progressive Low-grade Gliomas
- Pediatric Progressive Low-grade Gliomas

## Interventions

- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT01734512
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-13
- **Primary completion:** 2020-01-31
- **Final completion:** 2024-07-31
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2025-09-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01734512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01734512, "PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01734512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*